JAMA
Rarely used cholesterol test bests LDL for cardio risk
Clinical takeaway: ApoB may better align treatment with true cardiovascular risk and guide more appropriate therapy intensification.
Lipid management has long been guided by LDL, but this measure does not directly capture the number of circulating atherogenic particles that drive plaque formation. ApoB, which counts these particles, offers a more direct measure of risk and may better identify patients who would benefit from more intensive therapy.
LDL reflects the amount of cholesterol carried within particles, not the number of particles themselves. Because each particle can carry varying amounts of cholesterol, LDL levels may underestimate risk when particle numbers are high but cholesterol content per particle is low. In contrast, apoB measures the total number of atherogenic lipoprotein particles—each of which can enter the arterial wall and contribute to plaque formation.
In a computer simulation of 250,000 U.S. adults without cardiovascular disease, apoB-guided care outperformed LDL- and non-HDL–based strategies, yielding greater overall health gains. Compared with non-HDL approaches, apoB-based care was associated with roughly 1,300 additional quality-adjusted life-years and remained cost-effective.
ApoB-guided care led to more appropriate intensification of lipid-lowering therapy, including high-intensity statins and ezetimibe, with projected reductions in cardiovascular events over time. Despite this, apoB testing remains uncommon, in part because it requires an additional test and is not included in routine cholesterol panels.
Recent guideline updates further emphasize aggressive risk reduction. New recommendations presented at ACC 2026 support targeting LDL cholesterol below 55 mg/dL in higher-risk patients, reinforcing the need to more precisely identify who should receive intensified therapy.
“We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. healthcare payers,” said study lead author Ciaran Kohli-Lynch, assistant professor of preventive medicine in the division of epidemiology at Northwestern University Feinberg School of Medicine.
Source: Luebbe S, et al. JAMA. April 8, 2026. Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy. doi:10.1001/jama.2026.2986